| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | SB-225002 | CTRPv2 | pan-cancer | AAC | 0.067 | 0.03 |
| mRNA | BIBR-1532 | CTRPv2 | pan-cancer | AAC | 0.08 | 0.03 |
| mRNA | Axitinib | CTRPv2 | pan-cancer | AAC | 0.074 | 0.03 |
| mRNA | SR-II-138A | CTRPv2 | pan-cancer | AAC | 0.068 | 0.03 |
| mRNA | Dasatinib | CTRPv2 | pan-cancer | AAC | -0.077 | 0.03 |
| mRNA | triazolothiadiazine | CTRPv2 | pan-cancer | AAC | 0.064 | 0.03 |
| mRNA | tivozanib | GDSC1000 | pan-cancer | AAC | 0.075 | 0.03 |
| mRNA | NPC-26 | CTRPv2 | pan-cancer | AAC | 0.082 | 0.03 |
| mRNA | oligomycin a | CTRPv2 | pan-cancer | AAC | 0.075 | 0.03 |
| mRNA | tanespimycin:gemcitabine (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.068 | 0.03 |